Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSCI NYSE:CVM NASDAQ:KZIA NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSCICOSCIENS Biopharma$4.33+5.6%$3.56$1.96▼$6.77$12.90M0.7611,119 shs10,314 shsCVMCEL-SCI$3.96-5.0%$3.27$1.98▼$66.60$12.01M0.3205,141 shs417,623 shsKZIANovogen$10.15-1.2%$6.52$2.86▼$39.05$10.34M2.64374,015 shs48,991 shsWINTWindtree Therapeutics$1.19+13.3%$0.72$0.36▼$737.44$3.84M0.73.20 million shs19.25 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSCICOSCIENS Biopharma+6.91%+25.73%+23.01%+47.33%+432,999,900.00%CVMCEL-SCI-5.04%+12.18%+72.93%-48.19%-90.70%KZIANovogen-1.17%-6.02%+13.92%+207.58%-69.18%WINTWindtree Therapeutics+13.33%+63.01%+116.36%+4.39%-99.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACVMCEL-SCI0.1634 of 5 stars0.02.00.00.01.40.00.6KZIANovogen3.7543 of 5 stars3.85.00.00.02.10.00.0WINTWindtree Therapeutics2.9748 of 5 stars3.05.00.00.03.20.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSCICOSCIENS Biopharma 0.00N/AN/AN/ACVMCEL-SCI 0.00N/AN/AN/AKZIANovogen 3.50Strong Buy$14.0037.93% UpsideWINTWindtree Therapeutics 2.00Hold$350.0029,311.76% UpsideCurrent Analyst Ratings BreakdownLatest WINT, KZIA, CSCI, and CVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025KZIANovogenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$13.006/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSCICOSCIENS Biopharma$9.59M1.42N/AN/A$3.49 per share1.24CVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AKZIANovogen$1.51M6.79N/AN/A($9.87) per share-1.03WINTWindtree TherapeuticsN/AN/AN/AN/A$38.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSCICOSCIENS Biopharma-$15.31M-$5.80N/A∞N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)CVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AKZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/AWINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)Latest WINT, KZIA, CSCI, and CVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025WINTWindtree Therapeutics-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSCICOSCIENS BiopharmaN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSCICOSCIENS BiopharmaN/A2.882.54CVMCEL-SCI0.661.071.09KZIANovogenN/A0.21N/AWINTWindtree TherapeuticsN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSCICOSCIENS Biopharma0.73%CVMCEL-SCI12.08%KZIANovogen30.89%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipCSCICOSCIENS Biopharma0.10%CVMCEL-SCI9.93%KZIANovogen1.00%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSCICOSCIENS Biopharma203.15 million3.14 millionN/ACVMCEL-SCI433.03 million64.67 millionOptionableKZIANovogen121.01 million997,000OptionableWINTWindtree Therapeutics303.66 million3.65 millionNot OptionableWINT, KZIA, CSCI, and CVM HeadlinesRecent News About These CompaniesNasdaq Biotech Firm Windtree to Raise $200M for First-Ever BNB Crypto Treasury0July 18 at 9:17 AM | thecurrencyanalytics.comTBiotech Company Windtree to Raise Up to $200M for BNB TreasuryJuly 17 at 5:19 AM | coindesk.comBNB gains 3% following Windtree's plan to launch BNB treasury, H1 reportJuly 16 at 12:18 AM | fxstreet.comWindtree Becomes First NASDAQ Firm to Add BNB to Its Balance SheetJuly 16 at 7:17 PM | blockonomi.comWindtree to raise $200M to launch a BNB treasury strategyJuly 16 at 7:17 PM | msn.comWindtree Therapeutics, Inc. Announces $60 Million Securities Purchase Agreement to Launch BNB Crypto Treasury StrategyJuly 16 at 9:36 AM | quiverquant.comQWindtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On SubscriptionsJuly 16 at 9:22 AM | globenewswire.comWindtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - NasdaqJuly 4, 2025 | nasdaq.comWindtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart FailureJuly 2, 2025 | globenewswire.comWindtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim AnalysisJune 30, 2025 | finance.yahoo.comWindtree Therapeutics Signs Agreement to Cut PHEXXI Manufacturing Costs by Over 50% Through Partnership with Chinese ManufacturerJune 26, 2025 | quiverquant.comQWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelJune 26, 2025 | globenewswire.comWindtree Therapeutics Announces Promising Phase 2 Study Results for IstaroximeJune 17, 2025 | msn.comWindtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B StudyJune 16, 2025 | manilatimes.netMWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14, 2025 | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deWindtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 11, 2025 | tmcnet.comWindtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in RoyaltiesJune 11, 2025 | quiverquant.comQWorking to clean up its finances, Windtree Therapeutics gets into the garbage businessJune 10, 2025 | bizjournals.comWindtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services BusinessJune 10, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWINT, KZIA, CSCI, and CVM Company DescriptionsCOSCIENS Biopharma NASDAQ:CSCI$4.33 +0.23 (+5.61%) Closing price 07/18/2025 03:56 PM EasternExtended Trading$4.28 -0.05 (-1.27%) As of 07/18/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.CEL-SCI NYSE:CVM$3.96 -0.21 (-5.04%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.97 +0.01 (+0.25%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Novogen NASDAQ:KZIA$10.15 -0.12 (-1.17%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$9.67 -0.48 (-4.73%) As of 07/18/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Windtree Therapeutics NASDAQ:WINT$1.19 +0.14 (+13.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.19 +0.00 (+0.08%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
